Previous 10 | Next 10 |
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced it will host its fourth quarter and full year 2020 investor update conference call and webcast at 8:30 a.m. Eastern Time on Wednesday, February 17, 2021. Individuals interested in participating in the call should dial (83...
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a GI-focused healthcare company, will provide a corporate overview during a presentation and Q&A session at the 39 th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2021 at 5:20 p.m. Eastern Time. A live web...
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced the appointment of Jay P. Shepard to its Board of Directors, effective immediately. Mr. Shepard will also serve as a member of the Audit Committee. Following the appointment of Mr. Shepard, the Board is now composed of 11...
Ironwood Pharmaceuticals, Inc. (IRWD) Q3 2020 Results Earnings Conference Call November 5, 2020, 4:30 PM ET Company Participants Meredith Kaya - Vice President, Investor Relations and Corporate Communications Mark Mallon - Chief Executive Officer Mark Plinio - Chief Commercial Officer Gina Co...
Image source: The Motley Fool. Ironwood Pharmaceuticals Inc (NASDAQ: IRWD) Q3 2020 Earnings Call Nov 6, 2020 , 4:30 p.m. ET Operator Continue reading For further details see: Ironwood Pharmaceuticals Inc (IRWD) Q3 2020 Earnings Call Trans...
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will participate in a virtual fireside chat at the 29 th Annual Credit Suisse Healthcare Conference on Wednesday, November 11, 2020 at 3:30 p.m. Eastern Time. A live webcast of Ironwood’s fireside chat will be accessible t...
The following slide deck was published by Ironwood Pharmaceuticals, Inc. in conjunction with their 2020 Q3 earnings call. For further details see: Ironwood Pharmaceuticals, Inc. 2020 Q3 - Results - Earnings Call Presentation
Alongside its Q3 results last night, Ironwood Pharmaceuticals (IRWD) announced the appointment of Alexander Denner to the board, effective next week.Dr. Denner is the founder and CIO at Sarissa Capital Management.Board Chair Julie McHugh: "We believe [Denner's] wealth of knowledge will be inv...
Ironwood Pharmaceuticals (IRWD): Q3 Non-GAAP EPS of $0.23 beats by $0.08; GAAP EPS of $0.21 beats by $0.08.Revenue of $103.47M (-21.1% Y/Y) beats by $7.39M.FY20 guidance: Total Revenue of $370M–$385M from previous guidance of $360M–$380M vs consensus of $368.2M ; Adjusted EBITDA...
– U.S. LINZESS ® (linaclotide) net sales increased 10% year-over-year to $241 million, as reported by AbbVie Inc. (AbbVie) – – U.S. LINZESS collaboration revenue to Ironwood increased 18% year-over-year to $100 million, resulting in 3Q 2020 ...
News, Short Squeeze, Breakout and More Instantly...
Ironwood Pharmaceuticals Inc. Company Name:
IRWD Stock Symbol:
NASDAQ Market:
Ironwood Pharmaceuticals Inc. Website:
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that Sravan Emany, Chief Financial Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 9:00 a.m. ET at the Marriott Marquis in New York City. A live webcast of I...
2024-05-22 07:30:10 ET Wells Fargo analyst issues OVERWEIGHT recommendation for IRWD on May 22, 2024 05:13AM ET. The previous analyst recommendation was Overweight. IRWD was trading at $6.78 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
2024-05-22 07:00:07 ET Mohit Bansal from Wells Fargo issued a price target of $14.00 for IRWD on 2024-05-22 05:13:00. The adjusted price target was set to $14.00. At the time of the announcement, IRWD was trading at $6.78. The overall price target consensus is at $16.00 ...